MedTrace Logo

Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori

NCT00149084 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2006-09-11

No results posted yet for this study

Summary

The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor \[PPI\], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.

Conditions

  • Helicobacter Infections
  • Gastritis
  • Gastric Ulcer
  • Duodenal Ulcer

Interventions

DRUG

Lansoprazole, clarithromycin, amoxicillin

Sponsors & Collaborators

  • Yokoyama Foundation for Clinical Pharmacology

    collaborator OTHER

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Takahisa Furuta, MD, PhD · Center for Clinical Research, Hamamatsu University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00149084 on ClinicalTrials.gov